Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Rigel Pharmaceuticals posts record sales in Q4 2024, eyes growth

Rigel Pharmaceuticals reported robust financial performance in Q4 2024, with record sales and positive net income, driven by key product sales. The company's focus on innovation, pipeline progress, and financial discipline positions it well for sustained growth and market competitiveness. While facing challenges in meeting revenue targets and advancing clinical programs, Rigel has opportunities to expand its product offerings and market reach.

Rigel Pharmaceuticals reports stellar Q1 performance and optimistic 2025 outlook

Rigel Pharmaceuticals delivered strong financial results in Q1 2025, driven by robust net product sales and strategic decision-making. While facing challenges in program clarity and operational balance, the company's focus on growth and profitability positions them well for future opportunities.

Rigel Pharmaceuticals excels in Q2, raises revenue guidance significantly

Rigel Pharmaceuticals delivered robust financial performance in Q2 2025, marked by substantial revenue growth and promising developments in its product portfolio. While facing inquiries on specific sales and guidance aspects, the company's strategic focus on pipeline advancements and revenue projections underscores a positive outlook for future growth.

Rigel Pharmaceuticals excels in Q3, raises guidance amid pipeline progress

Rigel Pharmaceuticals delivered impressive financial results in Q3 2025, with strong revenue growth, profitability, and an optimistic outlook for the year. The company's focus on innovation, strategic collaborations, and financial discipline positions it well for future success in the oncology market. While challenges exist in maintaining growth momentum and navigating industry competition, Rigel Pharmaceuticals has opportunities to leverage its strengths and drive continued expansion.

Rigel Pharmaceuticals reports robust sales growth and eyes expansion opportunities

Rigel Pharmaceuticals showcased strong performance in net sales growth and a profitable financial position, driven by successful commercial products. While facing challenges in enrollment and market competitiveness, the company's strategic focus on hematology and oncology positions it for future growth. Opportunities lie in advancing R289, expanding the product pipeline, and optimizing sales strategies to drive continued success and revenue growth.